Wenxin Liu

BURDEN OF LYMPHOMA IN CHINA, 1990−2019: AN ANALYSIS OF GLOBAL BURDEN OF DISEASES, INJURIES, AND RISK FACTORS STUDY 2019

D. Zhao, Li-ping Wang, Jiangmei Liu, 2021, Hematological Oncology.

Abnormal immune function of MDSC and NK cells from chronic phase CML patients restores with tyrosine kinase inhibitors.

R. Wen, Wenxin Liu, Guo-Cai Wu, 2022, International immunopharmacology.

Results from the IMpower132 China cohort: Atezolizumab plus platinum‐based chemotherapy in advanced non‐small cell lung cancer

J. Yi, Jianxing He, Jinjing Xia, 2022, Cancer medicine.

A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYA

L. Sehn, M. Martelli, M. Trněný, 2020, Journal of Hematology & Oncology.

Health-related quality of life in the phase III GALLIUM study of obinutuzumab- or rituximab-based chemotherapy in patients with previously untreated advanced follicular lymphoma

J. Sancho, T. Kinoshita, A. Davies, 2020, Annals of Hematology.